Understanding the Value of Response and Early Tumour Shrinkage (ETS) in Pts with Wt kras MCRC Treated with Panitumumab (P) Plus Folfox (F)Jean‐Yves Douillard, R. Sidhu, Marc Peeters et al.|Annals of Oncology|2012Cited by 2
Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): A Number-Needed-To-Treat (NNT) AnalysisJean‐Yves Douillard, R. Sidhu, S. Sienna et al.|Value in Health|2013Cited by 1
Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus ChemotherapyJean‐Yves Douillard, Timothy Price, R. Sidhu et al.|Annals of Oncology|2012Cited by 1